Glioblastoma

Oncology·MeSH: Glioblastoma

Prevalence

3.2 / 100K

Incidence

3.2 / 100K/yr

107 drugs in development·47 companies·67 clinical trials

Drug Pipeline by Phase

Phase 2(29)
DrugCompany
[177Lu]Lu-DOTATATENovartis AG (NVS)
ad-rts-hil-12Alaunos Therapeutics, Inc. (TCRT)
azixaIMMUNE PHARMACEUTICALS INC (IMNP)
BDTX-1535Black Diamond Therapeutics, Inc. (BDTX)
BerubicinCNS Pharmaceuticals, Inc. (CNSP)
cemiplimabAlaunos Therapeutics, Inc. (TCRT)
DOC1021Black Diamond Therapeutics, Inc. (BDTX)
gadolinium-chelateGH Research PLC (GHRS)
ict-121EOM Pharmaceutical Holdings, Inc. (IMUC)
inb-400IN8BIO, INC. (INAB)
lomustineCNS Pharmaceuticals, Inc. (CNSP)
LomustineADMA BIOLOGICS, INC. (ADMA)
LomustineENANTA PHARMACEUTICALS INC (ENTA)
lsta1LISATA THERAPEUTICS, INC. (LSTA)
Montanide ISA 51 VGBlack Diamond Therapeutics, Inc. (BDTX)
N-803ENANTA PHARMACEUTICALS INC (ENTA)
PD-L1 t-haNKENANTA PHARMACEUTICALS INC (ENTA)
RelatlimabENANTA PHARMACEUTICALS INC (ENTA)
reyobiqPLUS THERAPEUTICS Inc. (PSTV)
ropidoxuridineShuttle Pharmaceuticals Holdings, Inc. (SHPH)
SargramostimBlack Diamond Therapeutics, Inc. (BDTX)
silevertinibBlack Diamond Therapeutics, Inc. (BDTX)
sl-701STEMLINE THERAPEUTICS INC (STML)
SVN53-67/M57-KLH Peptide VaccineBlack Diamond Therapeutics, Inc. (BDTX)
TemozolomideBioNTech SE (BNTX)
TemozolomideJazz Pharmaceuticals plc (JAZZ)
trc102Tracon Pharmaceuticals, Inc. (TCON)
veledimexAlaunos Therapeutics, Inc. (TCRT)
wp1066Moleculin Biotech, Inc. (MBRX)
Phase 1(32)
DrugCompany
[177Lu]Lu-DOTA-TATEPTC THERAPEUTICS, INC. (PTCT)
[68Ga]Ga-DOTA-TATEPTC THERAPEUTICS, INC. (PTCT)
ABBV-155Black Diamond Therapeutics, Inc. (BDTX)
ABBV-155PTC THERAPEUTICS, INC. (PTCT)
ABBV-155Merus N.V. (MRUS)
ABBV-637Merus N.V. (MRUS)
ABBV-637Black Diamond Therapeutics, Inc. (BDTX)
ABBV-637PTC THERAPEUTICS, INC. (PTCT)
CemiplimabActinium Pharmaceuticals, Inc. (ATNM)
CV09050101 mRNA vaccine RDE 100 μgCureVac N.V. (CVAC)
ERAS-801Merus N.V. (MRUS)
ERAS-801PTC THERAPEUTICS, INC. (PTCT)
ERAS-801Black Diamond Therapeutics, Inc. (BDTX)
ERAS-801Erasca, Inc. (ERAS)
immunizationBlack Diamond Therapeutics, Inc. (BDTX)
inb-200IN8BIO, INC. (INAB)
kros 201Kairos Pharma, LTD. (KAPA)
LY3214996ELI LILLY & Co (LLY)
mb-101MUSTANG BIO, INC. (MBIO)
mb-101Fortress Biotech Inc. (FBIO)
mb-101Fortress Biotech Inc. (FBIO)
mb-108Fortress Biotech Inc. (FBIO)
mb-109MUSTANG BIO, INC. (MBIO)
Mebendazole (improved formulation)Bullfrog AI Holdings Inc. (BFRG)
PD-L1 t-haNKImmunityBio, Inc. (IBRX)
pritumumabNascent Biotech Inc. (NBIO)
SelinexorBlack Diamond Therapeutics, Inc. (BDTX)
SelinexorPTC THERAPEUTICS, INC. (PTCT)
SelinexorMerus N.V. (MRUS)
ST101KYNTRA BIO INC. (KYNB)
TemozolomideKYNTRA BIO INC. (KYNB)
TN-TC11GBlack Diamond Therapeutics, Inc. (BDTX)
Phase 4(1)
DrugCompany
[177lu]lu-neobNovartis AG (NVS)

Compare drugs

carmustine vs [177Lu]Lu-DOTA-TATEcarmustine vs A10 and AS2-1 Antineoplastoncarmustine vs Antineoplastons (A10 & AS2-1)

Frequently asked questions

How many drugs are in development for Glioblastoma?

BioSniper tracks 107 drugs in development for Glioblastoma across 47 companies.

How many clinical trials target Glioblastoma?

There are 67 clinical trials targeting Glioblastoma tracked by BioSniper.

What is the prevalence of Glioblastoma?

The estimated prevalence of Glioblastoma is approximately 3.2 per 100,000 population.

Deep-dive into Glioblastoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis